Relay Therapeutics to Participate in Two Upcoming Investor Conferences
February 02, 2022 07:30 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Guggenheim Healthcare Talks 2022 Oncology Conference...
Relay Therapeutics Announces Dosing of First Patient in First-in-Human Trial of RLY-2608 and Initiation of Expansion Cohorts for First-In-Human Trial of RLY-4008
January 04, 2022 07:30 ET
|
Relay Therapeutics, Inc.
Doses first patient in first-in-human trial of RLY-2608, a pan-mutant and isoform-selective PI3Kα inhibitor Selects 70 mg once-daily dose for RLY-4008 and initiates expansion cohorts in patients...
Relay Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
January 03, 2022 07:30 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022...
Relay Therapeutics Announces Preclinical Data that Support Clinical Development of RLY-2608 as Both a Single Agent and in Combination
December 10, 2021 07:30 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
November 10, 2021 16:05 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Highlights
November 04, 2021 16:05 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
October 12, 2021 21:58 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics Announces Proposed Public Offering of Common Stock
October 11, 2021 16:15 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics Announces Interim Clinical Data that Support RLY-4008 as a Highly Selective FGFR2 Inhibitor
October 08, 2021 06:00 ET
|
Relay Therapeutics, Inc.
Interim data suggest that RLY-4008 is a highly selective FGFR2 inhibitor that has not shown to be limited by off-target toxicities of hyperphosphatemia (FGFR1) and diarrhea (FGFR4) RLY-4008...
Relay Therapeutics Announces Preclinical Data that Support RLY-2608 as the First Known Allosteric Pan-Mutant Selective Inhibitor of PI3Kα
October 07, 2021 08:50 ET
|
Relay Therapeutics, Inc.
RLY-2608 preferentially binds mutant PI3Kα at a novel allosteric site discovered by the Dynamo™ platform Preclinically, achieved tumor regressions in vivo with significantly reduced impact on glucose...